Bioavailability of magnesium from a sustained release supplement compared to a conventional supplement
- Conditions
- magnesium deficiencyhealthy volunteers
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
BMI between 18.5-29.9 kg / m²,
Ability and willingness of study participants to follow the doctor's instructions,
written consent of the subjects after detailed oral and written information on the study contents, requirements and risks
Allergy/intolerance to components of the administered test products,
Use of nutritional supplements and / or medicines with magnesium,
severe chronic diseases (diabetes type I, renal insufficiency, liver diseases, manifest cardiovascular diseases, cancer),
diagnosed blood coagulation disorders and anticoagulant medication, e.g. Marcumar (except ASS),
chronic diseases of the gastrointestinal tract (ulcerative colitis, Crohn's disease, pancreatic insufficiency),
regular intake of laxatives,
Pregnancy or lactation,
Alcohol, drug and / or drug dependence,
subjects who are incapable of giving consent,
Refusal or withdrawal of consent by the subject,
simultaneous participation in another clinical trial or participation within the past 30 days,
planned surgery in the next 3 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Magnesium excretion with the urine at the time point/period 0, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hrs. after ingestion of the test product.
- Secondary Outcome Measures
Name Time Method Magnesium concentration in serum at time 0 (fasting), 1, 2, 3, 4, 6 and 8 hours after ingestion of the test product.